Cathie Wood of ARK Invest continues to back gene editing company CRISPR Therapeutics, seeing its potential in transforming healthcare. Wood’s vision aligns with the technology’s ability to revolutionize disease treatment, akin to the impact of software on business operations. The recent purchases of CRISPR stock indicate a long-term commitment to this innovative sector.

ARK Invest recently acquired over 76,800 shares of CRISPR Therapeutics in just three trading days, totaling over $4.4 million. This move reflects Wood’s confidence in the company’s gene editing technology and its potential to disrupt various industries. Despite the stock’s volatility, Wood remains steadfast in her belief in CRISPR’s long-term promise.

CRISPR Therapeutics’ breakthrough gene editing therapy, exa-cel, for sickle cell disease and beta thalassemia, received FDA approval in December 2023. This milestone marks a significant shift from theoretical applications to real-world medical advancements. With a robust balance sheet and strategic collaborations, CRISPR is poised for further growth in the gene editing market.

The market has priced in high expectations for CRISPR Therapeutics, with shares surging since its IPO in October 2016. The company’s stock performance in 2025, up 40% year-to-date, outpaces the S&P 500, reflecting investor confidence in its innovative approach to genetic editing. Analyst revenue estimates for CRISPR show strong growth projections in the coming years, indicating a bright future for the company in the gene editing industry.

Read more at Yahoo Finance: Cathie Wood drops $1.3 million on healthcare stock